1093070-14-4 Usage
Uses
Used in Pharmaceutical Industry:
PLpro inhibitor is used as a potential antiviral drug for the treatment of COVID-19 and other coronavirus infections. It targets the papain-like protease (PLpro) enzyme, which is essential for the replication of these viruses. By inhibiting PLpro, the inhibitor can disrupt the viral replication cycle, potentially slowing down or preventing the spread of the virus within the body. This makes PLpro inhibitors a promising candidate for the development of new antiviral therapies to combat COVID-19 and similar infections.
Used in Research and Development:
PLpro inhibitor is used as a research tool in the study of coronavirus replication mechanisms and the development of new antiviral drugs. The inhibitor provides a means to specifically target and study the role of the papain-like protease (PLpro) enzyme in the replication of coronaviruses. This can help researchers better understand the virus's life cycle and identify potential therapeutic targets for the development of new antiviral drugs to treat COVID-19 and other similar infections.
Used in Clinical Trials:
PLpro inhibitor is used as a candidate for clinical trials to evaluate its effectiveness and safety in treating COVID-19 and other coronavirus infections. These trials are essential to determine the optimal dosage, potential side effects, and overall efficacy of the inhibitor as a potential antiviral drug. The results of these clinical trials will provide valuable information to guide the further development and potential approval of PLpro inhibitors for use in treating coronavirus infections.
Check Digit Verification of cas no
The CAS Registry Mumber 1093070-14-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,3,0,7 and 0 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1093070-14:
(9*1)+(8*0)+(7*9)+(6*3)+(5*0)+(4*7)+(3*0)+(2*1)+(1*4)=124
124 % 10 = 4
So 1093070-14-4 is a valid CAS Registry Number.
1093070-14-4Relevant articles and documents
COMPOUNDS AND METHODS FOR TREATING RESPIRATORY DISEASES
-
Page/Page column 27-28, (2011/11/12)
Described herein are compounds and compositions, and methods for using the compounds and compositions, for treating respiratory diseases and illness, such as severe acute respiratory syndrome (SARS).
Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome - Coronavirus papain-like protease
Ghosh, Arun K.,Takayama, Jun,Aubin, Yoann,Ratia, Kiira,Chaudhuri, Rima,Baez, Yahira,Sleeman, Katrina,Coughlin, Melissa,Nichols, Daniel B.,Mulhearn, Debbie C.,Prabhakar, Bellur S.,Baker, Susan C.,Johnson, Michael E.,Mesecar, Andrew D.
experimental part, p. 5228 - 5240 (2010/03/04)
We describe here the design, synthesis, molecular modeling, and biological evaluation of a series of small molecule, nonpeptide inhibitors of SARS-CoV PLpro. Our initial lead compound was identified via high-throughput screening of a diverse chemical library. We subsequently carried out structure - activity relationship studies and optimized the lead structure to potent inhibitors that have shown antiviral activity against SARS-CoV infected Vero E6 cells. Upon the basis of the X-ray crystal structure of inhibitor 24-bound to SARS-CoV PLpro, a drug design template was created. Our structure-based modification led to the design of a more potent inhibitor, 2 (enzyme IC50 = 0.46 μM; antiviral EC50 = 6 μM). Interestingly, its methylamine derivative, 49, displayed good enzyme inhibitory potency (IC50 = 1.3 μM) and the most potent SARS antiviral activity (EC50 = 5.2 μM) in the series. We have carried out computational docking studies and generated a predictive 3D-QSAR model for SARS-CoV PLpro inhibitors.
